SG11202006877PA - Anti-cd47 antibodies that do not cause significant red blood cell agglutination - Google Patents
Anti-cd47 antibodies that do not cause significant red blood cell agglutinationInfo
- Publication number
- SG11202006877PA SG11202006877PA SG11202006877PA SG11202006877PA SG11202006877PA SG 11202006877P A SG11202006877P A SG 11202006877PA SG 11202006877P A SG11202006877P A SG 11202006877PA SG 11202006877P A SG11202006877P A SG 11202006877PA SG 11202006877P A SG11202006877P A SG 11202006877PA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- red blood
- blood cell
- cause significant
- cell agglutination
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018074055 | 2018-01-24 | ||
| PCT/CN2019/072929 WO2019144895A1 (en) | 2018-01-24 | 2019-01-24 | Anti-cd47 antibodies that do not cause significant red blood cell agglutination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006877PA true SG11202006877PA (en) | 2020-08-28 |
Family
ID=67395823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006877PA SG11202006877PA (en) | 2018-01-24 | 2019-01-24 | Anti-cd47 antibodies that do not cause significant red blood cell agglutination |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210070855A1 (en) |
| EP (1) | EP3743108A4 (en) |
| JP (1) | JP2021511064A (en) |
| KR (1) | KR20200116109A (en) |
| CN (1) | CN111629754B (en) |
| AU (1) | AU2019212674A1 (en) |
| CA (1) | CA3089512A1 (en) |
| IL (1) | IL276188A (en) |
| SG (1) | SG11202006877PA (en) |
| TW (1) | TW201932493A (en) |
| WO (1) | WO2019144895A1 (en) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020259535A1 (en) * | 2019-06-25 | 2020-12-30 | 南京金斯瑞生物科技有限公司 | Anti-cd47/anti-tigit bispecific antibody, preparation method therefor and application thereof |
| EP4001309A4 (en) * | 2019-07-16 | 2023-08-16 | Nanjing GenScript Biotech Co., Ltd. | Anti-cd47/anti-ctla-4 bispecific antibody and preparation method therefor and application thereof |
| KR20220047277A (en) | 2019-07-16 | 2022-04-15 | 길리애드 사이언시즈, 인코포레이티드 | HIV Vaccines, and Methods of Making and Using the Same |
| TW202108631A (en) * | 2019-08-21 | 2021-03-01 | 大陸商和鉑醫藥（上海）有限責任公司 | A anti-cd47 antigen binding protein and use thereof |
| CN114555123B (en) | 2019-10-18 | 2024-04-02 | 四十七公司 | Combination therapy for the treatment of myelodysplastic syndrome and acute myeloid leukemia |
| MX2022005123A (en) | 2019-10-31 | 2022-05-30 | Forty Seven Inc | Anti-cd47 and anti-cd20 based treatment of blood cancer. |
| CN115397853A (en) | 2019-12-17 | 2022-11-25 | 辉瑞大药厂 | Antibody with specificity to CD47 and PD-L1 and application thereof |
| CR20220303A (en) | 2019-12-24 | 2022-09-02 | Gilead Sciences Inc | Diacylglycerol kinase modulating compounds |
| CN117964757A (en) | 2020-02-14 | 2024-05-03 | 吉利德科学公司 | Antibodies and fusion proteins that bind CCR8 and uses thereof |
| CN112679611B (en) * | 2021-01-18 | 2022-06-10 | 倍而达药业（苏州）有限公司 | Humanized CD47 antibody or antigen binding fragment thereof and application |
| CN115916963A (en) | 2020-03-27 | 2023-04-04 | 门德斯有限公司 | Ex vivo use of modified cells of leukemia origin for enhancing the efficacy of adoptive cell therapy |
| WO2022010806A1 (en) * | 2020-07-06 | 2022-01-13 | ALX Oncology Inc. | Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays |
| EP4192501A1 (en) * | 2020-08-04 | 2023-06-14 | Exelixis, Inc. | Cd47 binding agents and uses thereof |
| US12071481B2 (en) * | 2020-12-23 | 2024-08-27 | D-10 Therapeutics, Inc. | Anti-CD47 antibodies and uses thereof |
| EP4304633A1 (en) | 2021-03-12 | 2024-01-17 | Mendus B.V. | Methods of vaccination and use of cd47 blockade |
| TW202302145A (en) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | Co-inhibition of cd47/sirpα binding and nedd8-activating enzyme e1 regulatory subunit for the treatment of cancer |
| AU2022299051A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022297373A1 (en) | 2021-06-23 | 2024-01-04 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP2024522594A (en) | 2021-06-23 | 2024-06-21 | ギリアード サイエンシーズ， インコーポレイテッド | Diacylglycerol kinase modulating compounds |
| EP4376884A1 (en) * | 2021-07-30 | 2024-06-05 | Ludwig-Maximilians-Universität München | Anti-cd47 antibodies and use thereof |
| CA3234909A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| KR20240097895A (en) | 2021-10-29 | 2024-06-27 | 길리애드 사이언시즈, 인코포레이티드 | CD73 compound |
| EP4452414A2 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (en) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7 inhibitors |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TW202345901A (en) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | Combination therapy for treating colorectal cancer |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| CN117257935A (en) * | 2022-06-21 | 2023-12-22 | 广东菲鹏制药股份有限公司 | Preparation containing anti-CD 47 antibody or antigen binding fragment thereof, preparation method and application thereof |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| WO2024078604A1 (en) * | 2022-10-14 | 2024-04-18 | Nanjing Legend Biotech Co., Ltd. | Antibodies targeting cd47 and uses thereof |
| WO2024137852A1 (en) | 2022-12-22 | 2024-06-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024140993A2 (en) * | 2022-12-29 | 2024-07-04 | Shanghai Henlius Biotech, Inc. | Anti-cd47 antibodies and methods of use |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6818749B1 (en) * | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
| EP1693385A4 (en) * | 2003-11-11 | 2009-11-04 | Chugai Pharmaceutical Co Ltd | Humanized anti-cd47 antibody |
| NZ628314A (en) * | 2012-02-06 | 2017-01-27 | Inhibrx Lp | Cd47 antibodies and methods of use thereof |
| US20140140989A1 (en) * | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| CN107530421B (en) * | 2014-12-30 | 2021-07-20 | 细胞基因公司 | anti-CD 47 antibodies and uses thereof |
| CN106084052B (en) * | 2016-06-17 | 2019-12-27 | 长春金赛药业股份有限公司 | anti-CD 47 monoclonal antibody and application thereof |
| CN108779179B (en) * | 2016-11-28 | 2022-02-08 | 江苏恒瑞医药股份有限公司 | CD47 antibody, antigen binding fragment thereof and medical application thereof |
-
2019
- 2019-01-24 SG SG11202006877PA patent/SG11202006877PA/en unknown
- 2019-01-24 AU AU2019212674A patent/AU2019212674A1/en not_active Abandoned
- 2019-01-24 EP EP19743231.3A patent/EP3743108A4/en not_active Withdrawn
- 2019-01-24 TW TW108102787A patent/TW201932493A/en unknown
- 2019-01-24 CN CN201980009335.0A patent/CN111629754B/en active Active
- 2019-01-24 KR KR1020207024051A patent/KR20200116109A/en not_active Application Discontinuation
- 2019-01-24 WO PCT/CN2019/072929 patent/WO2019144895A1/en unknown
- 2019-01-24 US US16/964,828 patent/US20210070855A1/en not_active Abandoned
- 2019-01-24 JP JP2020540609A patent/JP2021511064A/en active Pending
- 2019-01-24 CA CA3089512A patent/CA3089512A1/en active Pending
-
2020
- 2020-07-21 IL IL276188A patent/IL276188A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019212674A1 (en) | 2020-09-03 |
| WO2019144895A1 (en) | 2019-08-01 |
| CN111629754B (en) | 2023-10-20 |
| US20210070855A1 (en) | 2021-03-11 |
| IL276188A (en) | 2020-09-30 |
| JP2021511064A (en) | 2021-05-06 |
| CA3089512A1 (en) | 2019-08-01 |
| CN111629754A (en) | 2020-09-04 |
| EP3743108A1 (en) | 2020-12-02 |
| TW201932493A (en) | 2019-08-16 |
| EP3743108A4 (en) | 2022-01-26 |
| KR20200116109A (en) | 2020-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276188A (en) | Anti-cd47 antibodies that do not cause significant red blood cell agglutination | |
| IL283006A (en) | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) | |
| IL273886A (en) | B cell maturation antigen binding proteins | |
| IL280780A (en) | Anti-tigit antibodies | |
| SI3331910T1 (en) | Monoclonal antibodies against human b cell maturation antigen (bcma) | |
| IL280013A (en) | Anti-il36r antibodies | |
| IL279352A (en) | Il-11ra antibodies | |
| HK1249452A1 (en) | Immune cell trapping devices and methods for making and using the same | |
| SG11202106171WA (en) | Anti-btla antibodies | |
| ZA201705120B (en) | Cell penetrating antibodies | |
| IL278862A (en) | Monospecific and multispecifc anti-tmeff2 antibodies and their uses | |
| GB201819540D0 (en) | T cell modification | |
| IL287440A (en) | Antigen specific cd19-targeted car-t cells | |
| IL281594A (en) | Anti-klrg1 antibodies | |
| SG11202008513WA (en) | De-immunised anti-erbb3 antibodies | |
| HUE053453T2 (en) | Immunoassay for whole blood samples | |
| GB201806084D0 (en) | Antibodies | |
| CA184843S (en) | Egg separator | |
| GB201819952D0 (en) | Antibodies | |
| GB201817313D0 (en) | Antibodies | |
| GB201817311D0 (en) | Antibodies | |
| GB201817312D0 (en) | Antibodies | |
| GB201817309D0 (en) | Antibodies | |
| GB201820547D0 (en) | Modified antibodies | |
| GB201806099D0 (en) | Galectin-10 Antibodies |